BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 34848831)

  • 21. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer.
    Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C
    BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.
    He HX; Gao Y; Fu JC; Zhou QH; Wang XX; Bai B; Li PF; Huang C; Rong QX; Ping LQ; He YX; Mao JY; Chen X; Huang HQ
    Oncoimmunology; 2021 Apr; 10(1):1907059. PubMed ID: 33889438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis.
    Wang YQ; Zhang Y; Jiang W; Chen YP; Xu SY; Liu N; Zhao Y; Li L; Lei Y; Hong XH; Liang YL; Li JY; Zhang LL; Yun JP; Sun Y; Li YQ; Ma J
    J Immunother Cancer; 2019 Nov; 7(1):298. PubMed ID: 31722750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression status of PD-L1 and B7-H3 in mesothelioma.
    Matsumura E; Kajino K; Abe M; Ohtsuji N; Saeki H; Hlaing MT; Hino O
    Pathol Int; 2020 Dec; 70(12):999-1008. PubMed ID: 33027549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer.
    Seo WI; Lee CH; Jung SJ; Lee DS; Park HY; Jeong DH; Kim W; Chung JI; Choi I
    Cancer Immunol Immunother; 2021 Nov; 70(11):3113-3122. PubMed ID: 33770210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma.
    Long L; Zhang L; Yang Y; Zhou Y; Chen H
    Immunotherapy; 2022 Apr; 14(6):419-431. PubMed ID: 35187955
    [No Abstract]   [Full Text] [Related]  

  • 28. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer.
    Zong L; Mo S; Sun Z; Lu Z; Yu S; Chen J; Xiang Y
    Mod Pathol; 2022 Feb; 35(2):266-273. PubMed ID: 34493823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic impact of B7-H3 and B7-H4 in head and neck squamous cell carcinoma.
    Borgmann M; Oetting A; Meyer F; Möckelmann N; Droste C; von Bargen CM; Möller-Koop C; Witt M; Borgmann K; Rothkamm K; Betz C; Münscher A; Clauditz TS; Rieckmann T
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3383-3393. PubMed ID: 35941227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma.
    Chen H; Molberg K; Carrick K; Niu S; Rivera Colon G; Gwin K; Lewis C; Zheng W; Castrillon DH; Lucas E
    Mod Pathol; 2022 Dec; 35(12):1955-1965. PubMed ID: 35804040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
    Yang W; Lu YP; Yang YZ; Kang JR; Jin YD; Wang HW
    J Obstet Gynaecol Res; 2017 Oct; 43(10):1602-1612. PubMed ID: 28833798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression and Clinical Significance of Immune Checkpoint Regulator B7-H3 (CD276) in Human Meningioma.
    Deng J; Ma M; Wang D; Zhu H; Hua L; Sun S; Chen H; Cheng H; Qian ZR; Xie Q; Zhang T; Gong Y
    World Neurosurg; 2020 Mar; 135():e12-e18. PubMed ID: 31629137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 36. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
    Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
    Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S
    Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
    Russell-Goldman E; Kravets S; Dahlberg SE; Sholl LM; Vivero M
    Cancer Cytopathol; 2018 Apr; 126(4):253-263. PubMed ID: 29405663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
    Reddy OL; Shintaku PI; Moatamed NA
    Diagn Pathol; 2017 Jun; 12(1):45. PubMed ID: 28623908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma.
    Loch FN; Kamphues C; Beyer K; Schineis C; Rayya W; Lauscher JC; Horst D; Dragomir MP; Schallenberg S
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.